Lb Pharmaceuticals Inc (LBRX) is trading up at $39.42 (+0.48%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
Analyst price targets on LBRX
One firm's current price target on Lb Pharmaceuticals Inc: $68 — 73% above the current $39.4. Each is tracked to its date and scored the same way a member's call is.
- Needham $37.3 → $68 by Oct 2027 Oct 2, 2026 via Investing.com · Needham's track record
Targets published by research firms, extracted from the news, checked against independent reporting, and linked to their source. Where a firm did not state a horizon the target is tracked as 12 months, the industry convention; the rows where the firm set its own horizon are marked. Reported here as facts about what was published — not recommendations from Dalsna Finance, and no firm listed is affiliated with this site.
Lb Pharmaceuticals Inc net income history (FY2024–FY2025)
| FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|
| Income statement | ||
| Net income | −$63.1M | −$25.2M |
| EPS (diluted) | −$176.15 | −$3.13 |
| Balance sheet | ||
| Cash and equivalents | $23.0M | $250.2M |
| Total assets | $33.5M | $312.9M |
| Total liabilities | $13.8M | $11.6M |
| Shareholders' equity | −$94.6M | $301.3M |
| Cash flow | ||
| Operating cash flow | −$53.1M | −$35.2M |
| Capital expenditure | $769.0K | $52.0K |
| Free cash flow | −$53.8M | −$35.3M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Net income | −$14.2M | −$5.07M | −$5.31M | −$4.87M | −$3.56M | −$11.5M | −$19.1M | −$51.6M |
| EPS (diluted) | −$39.49 | −$14.00 | −$14.79 | −$13.58 | −$0.61 | $25.85 | −$0.67 | −$1.71 |
| Balance sheet | ||||||||
| Cash and equivalents | — | $23.0M | — | — | $269.7M | $250.2M | $320.7M | $283.1M |
| Total assets | — | $33.5M | — | — | $320.7M | $312.9M | $393.5M | $361.7M |
| Total liabilities | — | $13.8M | — | — | $10.5M | $11.6M | $14.8M | $29.3M |
| Shareholders' equity | −$91.5M | −$94.6M | −$99.3M | −$103.9M | $310.2M | $301.3M | $378.7M | $332.3M |
| Cash flow | ||||||||
| Operating cash flow | — | −$5.67M | −$8.13M | −$5.60M | −$3.37M | −$18.1M | −$23.3M | −$37.6M |
| Capital expenditure | — | $238.0K | $21.0K | −$9.00K | $0 | $40.0K | $32.0K | $363.0K |
| Free cash flow | — | −$5.90M | −$8.15M | −$5.59M | −$3.37M | −$18.1M | −$23.3M | −$38.0M |
From Lb Pharmaceuticals Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Lb Pharmaceuticals Inc
- Headquarters
- New York, New York From SEC filings, Oct 2026
Recent News (5)
-
LB Pharmaceuticals to Participate in Upcoming Investor Events NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-i…
-
LB Pharmaceuticals presents data on LB-102 at ECNP congress
LB Pharmaceuticals presents data on LB-102 at ECNP congress
-
-
LB Pharmaceuticals Reports Inducement Grants to New Employee Under Nasdaq Listing Rule 5635(c)(4) LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dime…
-
Needham initiates LB Pharmaceuticals stock with buy rating
Needham initiates LB Pharmaceuticals stock with buy rating
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International